Cannabis Investments

Below are the top five companies in the Pharmaceuticals industry as measured by lowest relative performance. Some analysts believe that stocks with lower relative performance are a better bargain. Jazz Pharmaceuticals (NASDAQ:JAZZ) ranks first with a loss of 8.17%; Nektar Therapeutics (NASDAQ:NKTR) ranks second with a loss of 4.63%; and BMP Sunstone (NASDAQ:BJGP) ranks third with a loss of 2.89%. Biodel (NASDAQ:BIOD) follows with a loss of 2.54% and Merck (NYSE:MRK) rounds out the top five with a loss of 2.16%. SmarTrend is bullish on shares of BIOD and our subscribers were alerted to Buy on March 01, 2010 at $4.38. The stock has risen 22.8% since the alert was issued.

From atop Bayer and Nektar Therapeutics’ new home in SF, developed by Alexandria Real Estate Equities

Aradigm Corporation – Medical Equipment – Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Aradigm Corporation (Aradigm) is a specialty pharmaceutical company engaged in the development and commercialization of drugs delivered by inhalation for treating severe respiratory diseases by pulmonologists. It has developed pulmonary drug delivery system, AERx Essence and AERx Strip Technology for the delivery of drugs to the target. The company’s current pipeline comprises of products used for treating cystic fibrosis, inhalation anthrax and bronchiectasis. Additionally, it plans to use its technology for tobacco smoking cessation therapy. Aradigm is headquartered at Hayward in California, the US.

And More inside the report…

Recent Developments

Aug 06, 2009: Aradigm Reports Net Loss Of $4.6 Million In Q2 2009
Jul 23, 2009: Aradigm Gets FDA Clearance For Phase IIb Ciprofloxacin Trial
May 12, 2009: Aradigm Posts Net Loss Of $5.2 Million For Q1 2009

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including mergers & acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick “one-stop-shop” to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.

Company Mentioned
The following companies are the major competitors of Aradigm Corporation:
Bayer HealthCare AG
Nektar Therapeutics
Pfizer Inc.

For more information, please visit:

http://www.aarkstore.com/reports/Aradigm-Corporation-Medical-Equipment-Deals-and-Alliances-Profile-38707.html

Or email us at press@aarkstore.com or call +919272852585

02/17/10 – www.TheTechTrader.com – China Agritech (CAGC), one of the strongest Chinese stocks out there right now, was up 1.75 or 9.02% on 2.2 million shares today. Thats nearly four points just in the last couple sessions, all time high territory. Cyclacel Pharmaceuticals Inc. (CYCC), added to our portfolio today, was up .37 or 15.4% on 13.7 million shares. If it gets any kind of follow through this stock should get up and test 4.00 pretty quickly, beyond that this stock could be one of those flyers that sees 6-7-8.00 down the road depending on news. Houston American Energy Corp. (HUSA) has been flying the last couple sessions. Up another 1.12 today or 11% on 627000 shares. We very might well get a test of the 12.75-85 that it hit back in 08. Sketchers USA (SKX) was up 1.00 or 3.44% on 1.5 million shares. If it gets over 31.62 this stock could accelerate higher, a target in the 40 41 range is doable. Ultra Clean Holdings (UCTT) had a very significant day technically today. Up 1.79 or 25.39% on 1.4 million shares, the heaviest volume since June. Any additional move could get this to the 11.50 area, short-term target, secondary target set at 14. http – Other stocks on Harry’s list today are Acme Packet, Inc. (APKT), Brigham Explorations (BEXP), Culp (CFI), Finisar (FNSR), Integrated Silicon Solutions (ISSI), Micrus Endovascular Corp. (MEND), Momenta Pharmaceuticals (MNTA), Nektar Therapeutics (NKTR), Netlist Inc. (NLST), Pharmacyclics (PCYC), TASER International Inc. (TASR …

01/27/10 – www.TheTechTrader.com – Tonight we’re covering both junior oil or junior biotech stocks that may have a chance of bouncing back in the next couple sessions and may be good for short-term swing-type trading. Amylin Pharmaceutical (AMLN) was down .24 or 1.26% on 6 million shares today. It finally broke out of a base pattern it’s been in for about a year and appears to be a mode where it can move higher with a target around the 23.00 level short-term and current support around the 16.50 area. Energy XXI (EXXI) is up .24 or 7% on 6.2 million. It jumped .24 or 7% on 6.2 million. Next target up around 4.75, secondary target around the 6.00 level. Toreador Resources (TRGL) has gone from 2.00 to 13.00 since March 09 and looks like a 16.50-17.00 stock short-term. Today it’s up .14 or 1.09% on 436000 shares. Xyratex (XRTX), a current portfolio position, was down .10 or .66% on 347000 shares. Even though it was down just a little today, it has a beautiful rising channel, testing support at 15.83 and could see 20.00, the next trading target. Other stocks on Harry’s list of junior oil stocks are Callon Petroleum (CPE) and McMoRan Exploration (MMR), and junior biotech stocks are Hollysys Automation (HOLI), Map Pharmaceuticals (MAPP), Momenta Pharmaceuticals (MNTA), Nektar Therapeutics (NKTR), RealNetworks (RNWK), RXi Pharmaceuticals (RXII), Salix Pharmaceuticals (SLXP), Spreadtrum Communications (SPRD) – https -Chart Info: Harry’s Chart of the Day, published each evening …